A Phase 2 interventional study of Zanubrutinib 80 MG in IgG4 Related Disease, sponsored by Matthew C. Baker. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Matthew C. Baker · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Immunoglobulin G4-Related Disease with a site in United States — 3 open to participants now, 7 under way, 3 of them phase 3. Immunoglobulin G4-Related Disease · United States.
Among the 14 studies in Immunoglobulin G4-Related Disease with a site in United States, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 8th registered.
73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.
Browse Immunoglobulin G4-Related Disease studies →3 of the 14 studies in Immunoglobulin G4-Related Disease with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States, Brazil, China and 5 more countries
Ages 2–18
Sanofi · Sites in United States, Argentina, Belgium and 16 more countries
Ages 18+
Emory University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 3
First in 2012; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 48 across 52 interventional studies indexed under Immunoglobulin G4-Related Disease.
Median enrollment 18 across the 12 interventional studies, 1,506 across the 2 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 10 most frequent:
Matthew C. Baker is the lead sponsor of 2 studies on the registry; none are open to participants now.
Matthew C. Baker has 1 study filed under Immunoglobulin G4-Related Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Immunoglobulin G4-Related Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
This will be a single-site, open-label study in symptomatic patients with IgG4-related disease affecting the submandibular and/or lacrimal glands. All patients will receive zanubrutinib orally at a dose of 80mg BID for 24 weeks.
The primary objective of this study is to demonstrate that zanubrutinib treatment reduces reduces the volume of the submandibular and/or lacrimal glands on PET/MRI at week 24 compared to baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the lacrimal gland confirmed by international consensus pathology criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zanubrutinib orally at a dose of 80mg BID for 24 weeks
Drug: Zanubrutinib 80 MG
Zanubrutinib 80 MG for 24 weeks
Volume of the Submandibular Glands on PET-MRI
To demonstrate that zanubrutinib treatment reduces the volume of the submandibular glands on PET-MRI at week 24 compared to Baseline.
Time frame: Baseline and Week 24
Volume of the Lacrimal Glands on PET-MRI
To demonstrate that zanubrutinib treatment reduces the volume of the lacrimal glands on PET-MRI at Week 24 compared to Baseline.
Time frame: Baseline and Week 24
FDG Avidity (SUVmax) of the Submandibular Glands on PET
Effect of zanubrutinib on change in FDG avidity (SUVmax) of the submandibular glands on PET at Weeks 12 and 24 compared to Baseline.
Time frame: Baseline, Week 12, and Week 24
FDG Avidity (SUVmax) of the Lacrimal Glands on PET
Effect of zanubrutinib on change in FDG avidity (SUVmax) of the lacrimal glands on PET at Week 24 compared to Baseline.
Time frame: Baseline, Week 12, and Week 24
Change in Total Metabolic Lesion Volume (tMLV) of Lacrimal Glands, Submandibular Glands, Parotid Glands, and Lymph Notes on PET
Time frame: Baseline, Week 12, and Week 24
Change in Total Lesion Glycolysis (TLG) of Submandibular and/or Lacrimal Glands on PET
Time frame: Baseline, Week 12, and Week 24
Change in Submandibular Glands on MRI
Change in parenchymal architecture scored 0 to 4 and sialography scored 0 to 4 where 0 is normal, healthy gland and 4 is worse outcome.
Time frame: Baseline, Week 12, and Week 24
Change in Parotid Glands on MRI
Change in parenchymal architecture scored 0 to 4 and sialography scored 0 to 4, where 0 is normal, healthy gland and 4 is worse outcome.
Time frame: Baseline, Week 12, and Week 24
Change in Lacrimal Glands on MRI
Change in parenchymal architecture scored 0 to 4, where 0 is normal, healthy gland and 4 is worse outcome.
Time frame: Baseline, Week 12, and Week 24
Change in the Volume of the Parotid Glands on PET/MRI
Time frame: Baseline, Week 12, and Week 24
Change in the Volume of the Submandibular Glands on PET/MRI
Time frame: Baseline and Week 12
Change in the Volume of the Lacrimal Glands on PET/MRI
Time frame: Baseline, and Week 12
Change in Serum IgG4 Level
Time frame: Baseline, Week 12, and Week 24
Change in Plasmablast Count
Change in percentage of CD19+ B cells in blood
Time frame: Baseline, Week 12, and Week 24
Change in Absolute Regulatory B Cell Count
Percentage of regulatory B cells in the blood, assessed using flow cytometry.
Time frame: Baseline, Week 12, and Week 24
Change in the IgG4-RD Responder Index
The IgG4-RD Responder Index detects change in disease activity and identifies improvements/worsening in the same or different organ systems. It encompasses more than 25 organs/sites and records the following for each organ/site: (i) activity trend (through a 0-3 \[normal/resolved - worsening\] organ/site score); (ii) presence of symptoms due to active disease; (iii) need for urgent care; (iv) presence of damage; and (v) presence of symptoms due to damage. The final activity score at each visit is obtained by summing all organ/site scores (i) and by doubling items needing urgent care (iii). The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity. A score of 0 represents no disease activity other than residual fibrosis.
Time frame: Baseline, Week 12, and Week 24
Proportion of Patients With no Disease Flares
Number and percentage of patients who did not have an IgG4-RD flare
Time frame: Week 12 to Week 24
Change in Total Salivary Grey Scale Ultrasound Score (TUS)
Each parotid and submandibular gland scored from 0 to 3 with a higher score indicating worse disease, total summed scores across all four glands will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)
Time frame: Baseline, Week 12, and Week 24
Change in Highest Score Among the Salivary Glands for the Grey Scale Ultrasound Score (HSUS)
Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, highest score will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)
Time frame: Baseline, Week 12, and Week 24
Change in Glandular Inflammation Total Ultrasound Score (iTUS)
Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, total summed scores across all four glands will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)
Time frame: Baseline, Week 12, and Week 24
Change in Highest Score Among the Salivary Glands for the Glandular Inflammation Ultrasound Score (iHSUS)
Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, highest score will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)
Time frame: Baseline, Week 12, and Week 24
Change in Physician Global Assessment of Disease
Symptoms rated on a 100 mm visual analog scale (VAS). Score range: 0 to 100, higher scores correspond to worse disease state.
Time frame: Baseline, Week 12, and Week 24
Change in Patient Global Assessment of Disease
Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state.
Time frame: Baseline, Week 12, and Week 24
Change in VAS for Ocular Symptoms - Dryness
Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state.
Time frame: Baseline to Week 24
Change in VAS for Dryness Symptoms
Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to more dryness. Participants were asked to assess their dryness, taking into account all areas, including ocular and salivary symptoms.
Time frame: Baseline, Week 12, Week 24
Change in FACIT-F Fatigue Score
Total score range: 0-52, lower scores correspond with more fatigue. FACIT = Functional Assessment of Chronic Illness Therapy.
Time frame: Baseline, Week 12, and Week 24
Change in RAND Short Form-36
The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
Time frame: Baseline, Week 12, and Week 24
Change in C3 Lab
Complement component 3 (C3) level in blood
Time frame: Baseline, Week 12, and Week 24
Change in C4 Lab
Complement component 4 (C4) level in blood
Time frame: Baseline, Week 12, and Week 24
Change in Total IgG Lab
Time frame: Baseline, Week 12, and Week 24
Change in IgE Lab
Time frame: Baseline, Week 12, and Week 24
Change in IgG1 Lab
Time frame: Baseline, Week 12, and Week 24
Change in ESR Lab
Change in erythrocyte sedimentation rate (ESR)
Time frame: Baseline, Week 12, and Week 24
Change in CRP Lab
Change in serum C-reactive protein (CRP) level
Time frame: Baseline, Week 12, and Week 24
Incidence of Safety Parameters Including Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs).
Time frame: Baseline to Week 32
Incidence of Safety Parameters Including Abnormal Laboratory Results
Number of participants with any grade 3 or 4 treatment-emergent laboratory abnormality
Time frame: Baseline to Week 32
| Milestone | Zanubrutinib |
|---|---|
| Started | 10 |
| Completed week 12 imaging | 8 |
| Completed week 24 imaging | 7 |
| Completed | 7 |
| Not completed | 3 |
To demonstrate that zanubrutinib treatment reduces the volume of the submandibular glands on PET-MRI at week 24 compared to Baseline.
| cm^3 | Zanubrutinib |
|---|---|
| Baseline | 12.7 ± 5.78 |
| Week 24 | 9.34 ± 4.80 |
| Change from Baseline at Week 24 | -3.37 ± 2.40 |
To demonstrate that zanubrutinib treatment reduces the volume of the lacrimal glands on PET-MRI at Week 24 compared to Baseline.
| cm^3 | Zanubrutinib |
|---|---|
| Baseline | 2.59 ± 2.18 |
| Week 24 | 1.17 ± 0.520 |
| Change from Baseline at Week 24 | -1.42 ± 1.76 |
Effect of zanubrutinib on change in FDG avidity (SUVmax) of the submandibular glands on PET at Weeks 12 and 24 compared to Baseline.
| kg/L | Zanubrutinib |
|---|---|
| Baseline | 5.33 ± 3.77 |
| Week 12 | 3.42 ± 1.26 |
| Change from Baseline at Week 12 | -1.91 ± 3.14 |
| Week 24 | 3.27 ± 1.05 |
| Change from Baseline at Week 24 | -2.06 ± 3.41 |
Effect of zanubrutinib on change in FDG avidity (SUVmax) of the lacrimal glands on PET at Week 24 compared to Baseline.
| kg/L | Zanubrutinib |
|---|---|
| Baseline | 5.52 ± 2.48 |
| Week 12 | 3.37 ± 1.18 |
| Change from Baseline at Week 12 | -2.15 ± 2.45 |
| Week 24 | 3.23 ± 1.27 |
| Change from Baseline at Week 24 | -2.29 ± 2.90 |
| cm^3 | Zanubrutinib |
|---|---|
| Baseline | 24.3 ± 20.6 |
| Week 12 | 5.19 ± 2.10 |
| Change from Baseline at Week 12 | -19.2 ± 20.5 |
| Week 24 | 3.64 ± 2.56 |
| Change from Baseline at Week 24 | -20.7 ± 22.4 |
| grams | Zanubrutinib |
|---|---|
| Baseline | 103 ± 92.1 |
| Week 12 | 16.1 ± 7.54 |
| Change from Baseline at Week 12 | -86.7 ± 91.3 |
| Week 24 | 11.2 ± 9.91 |
| Change from Baseline at Week 24 | -91.6 ± 98.5 |
Change in parenchymal architecture scored 0 to 4 and sialography scored 0 to 4 where 0 is normal, healthy gland and 4 is worse outcome.
| score on a scale | Zanubrutinib |
|---|---|
| Baseline (architecture) | 1.13 ± 0.500 |
| Week 12 (architecture) | 1.25 ± 0.577 |
| Change from Baseline at Week 12 (architecture) | 0.125 ± 0.342 |
| Week 24 (architecture) | 1.38 ± 0.806 |
| Change from Baseline at Week 24 (architecture) | 0.250 ± 0.683 |
| Baseline (saliography) | 1.00 ± 0 |
| Week 12 (saliography) | 1.00 ± 0 |
| Change from Baseline at Week 12 (sialography) | 0 ± 0 |
| Week 24 (sialography) | 1.00 ± 0 |
| Change from Baseline at Week 24 (sialography) | 0 ± 0 |
Change in parenchymal architecture scored 0 to 4 and sialography scored 0 to 4, where 0 is normal, healthy gland and 4 is worse outcome.
| score on a scale | Zanubrutinib |
|---|---|
| Baseline (architecture) | 2.13 ± 0.957 |
| Week 12 (architecture) | 1.63 ± 0.719 |
| Change from Baseline at Week 12 (architecture) | -0.500 ± 0.730 |
| Week 24 (architecture) | 1.63 ± 0.719 |
| Change from Baseline at Week 24 (architecture) | -0.500 ± 0.730 |
| Baseline (sialography) | 1.13 ± 0.342 |
| Week 12 (sialography) | 1.13 ± 0.342 |
| Change from Baseline at Week 12 (sialography) | 0 ± 0 |
| Week 24 (sialography) | 1.13 ± 0.342 |
| Change from Baseline at Week 24 (sialography) | 0 ± 0 |
Change in parenchymal architecture scored 0 to 4, where 0 is normal, healthy gland and 4 is worse outcome.
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 2.13 ± 1.09 |
| Week 12 | 2.50 ± 0.894 |
| Change from Baseline at Week 12 | 0.375 ± 0.500 |
| Week 24 | 2.69 ± 0.946 |
| Change from Baseline at Week 24 | 0.563 ± 0.814 |
| cm^3 | Zanubrutinib |
|---|---|
| Baseline | 44.6 ± 14.6 |
| Week 12 | 39.6 ± 11.6 |
| Change from Baseline at Week 12 | -5.07 ± 5.04 |
| Week 24 | 38 ± 11.7 |
| Change from Baseline at Week 24 | -6.66 ± 5.04 |
| cm^3 | Zanubrutinib |
|---|---|
| Baseline | 12.7 ± 5.78 |
| Week 12 | 10.0 ± 4.97 |
| Change from Baseline at Week 12 | -2.69 ± 2.35 |
| cm^3 | Zanubrutinib |
|---|---|
| Baseline | 2.59 ± 2.18 |
| Week 12 | 1.50 ± 0.89 |
| Change from Baseline at Week 12 | -1.09 ± 1.38 |
| cm^3 | Zanubrutinib |
|---|---|
| Baseline | 44.6 ± 14.6 |
| Week 12 | 39.6 ± 11.6 |
| Change from Baseline at Week 12 | -5.07 ± 5.04 |
| Week 24 | 38 ± 11.7 |
| Change from Baseline at Week 24 | -6.66 ± 5.04 |
| mg/dL | Zanubrutinib |
|---|---|
| Baseline | 643 ± 567 |
| Week 12 | 342 ± 305 |
| Change from Baseline at Week 12 | -301 ± 278 |
| Week 24 | 226 ± 179 |
| Change from Baseline at Week 24 | -413 ± 443 |
Change in percentage of CD19+ B cells in blood
| percentage of cells | Zanubrutinib |
|---|---|
| Baseline | 17.8 ± 25.2 |
| Week 12 | 0.175 ± 0.205 |
| Change from Baseline at Week 12 | -17.6 ± 25.1 |
| Week 24 | 0.213 ± 0.259 |
| Change from Baseline at Week 24 | -19.6 ± 26.5 |
Percentage of regulatory B cells in the blood, assessed using flow cytometry.
| percentage of cells | Zanubrutinib |
|---|---|
| Baseline | 3.03 ± 2.53 |
| Week 12 | 0.538 ± 1.03 |
| Change from Baseline at Week 12 | -2.49 ± 2.40 |
| Week 24 | 0.450 ± 0.404 |
| Change from Baseline at Week 24 | -2.58 ± 2.39 |
The IgG4-RD Responder Index detects change in disease activity and identifies improvements/worsening in the same or different organ systems. It encompasses more than 25 organs/sites and records the following for each organ/site: (i) activity trend (through a 0-3 \[normal/resolved - worsening\] organ/site score); (ii) presence of symptoms due to active disease; (iii) need for urgent care; (iv) presence of damage; and (v) presence of symptoms due to damage. The final activity score at each visit is obtained by summing all organ/site scores (i) and by doubling items needing urgent care (iii). The IgG4-RD Responder Index Total Activity Score ranges from 0 to a maximum of 162. Higher scores represent greater (i.e. worse) disease activity. A score of 0 represents no disease activity other than residual fibrosis.
| units on a scale | Zanubrutinib |
|---|---|
| Baseline | 6.63 ± 0.916 |
| Week 12 | 2.38 ± 2.07 |
| Change from Baseline at Week 12 | -4.25 ± 2.49 |
| Week 24 | 2.00 ± 2.20 |
| Change from Baseline at Week 24 | -4.63 ± 2.62 |
Number and percentage of patients who did not have an IgG4-RD flare
| Participants | Zanubrutinib |
|---|---|
| Proportion of Patients With no Disease Flares | 7 |
Each parotid and submandibular gland scored from 0 to 3 with a higher score indicating worse disease, total summed scores across all four glands will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 5.3 ± 3.8 |
| Week 12 | 4.4 ± 3.0 |
| Change from Baseline at Week 12 | -0.88 ± 1.25 |
| Week 24 | 3.5 ± 1.9 |
| Change from Baseline at Week 24 | -1.75 ± 2.19 |
Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, highest score will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 2.3 ± 0.71 |
| Week 12 | 1.9 ± 0.84 |
| Change from Baseline at Week 12 | -0.38 ± 0.52 |
| Week 24 | 1.6 ± 0.74 |
| Change from Baseline at Week 24 | -0.63 ± 0.52 |
Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, total summed scores across all four glands will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 7.4 ± 2.7 |
| Week 12 | 6.4 ± 1.6 |
| Change from Baseline at Week 12 | -1.00 ± 1.77 |
| Week 24 | 5.3 ± 1.5 |
| Change from Baseline at Week 24 | -2.13 ± 2.70 |
Each parotid and submandibular gland (n=4) scored from 0 to 3 with a higher score indicating worse disease, highest score will be assessed for change (overall score range: 0 to 12, with a higher score indicating worse disease)
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 2.4 ± 0.92 |
| Week 12 | 2.1 ± 0.84 |
| Change from Baseline at Week 12 | -0.25 ± 0.46 |
| Week 24 | 1.8 ± 0.71 |
| Change from Baseline at Week 24 | -0.63 ± 0.74 |
Symptoms rated on a 100 mm visual analog scale (VAS). Score range: 0 to 100, higher scores correspond to worse disease state.
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 68.4 ± 12.7 |
| Week 12 | 21.4 ± 29.4 |
| Change from Baseline at Week 12 | -47.0 ± 27.8 |
| Week 24 | 17.4 ± 29.3 |
| Change from Baseline at Week 24 | -51.0 ± 28.3 |
Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state.
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 52.4 ± 19.6 |
| Week 12 | 38.4 ± 30.4 |
| Change from Baseline at Week 12 | -14.0 ± 27.1 |
| Week 24 | 31.0 ± 25.8 |
| Change from Baseline at Week 24 | -21.4 ± 26.6 |
Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state.
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 47.6 ± 25.3 |
| Week 12 | 31.9 ± 20.9 |
| Change from Baseline at Week 12 | -15.8 ± 28.9 |
| Week 24 | 21.5 ± 15.1 |
| Change from Baseline at Week 24 | -26.1 ± 32.7 |
Symptoms rated on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to more dryness. Participants were asked to assess their dryness, taking into account all areas, including ocular and salivary symptoms.
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 47.6 ± 25.3 |
| Week 12 | 31.9 ± 20.9 |
| Change from Baseline at Week 12 | -15.8 ± 28.9 |
| Week 24 | 21.5 ± 15.1 |
| Change from Baseline at Week 24 | -26.1 ± 32.7 |
Total score range: 0-52, lower scores correspond with more fatigue. FACIT = Functional Assessment of Chronic Illness Therapy.
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 38.9 ± 14.0 |
| Week 12 | 41.6 ± 9.12 |
| Change from Baseline at Week 12 | 2.75 ± 10.4 |
| Week 24 | 43.3 ± 5.80 |
| Change from Baseline at Week 24 | 4.38 ± 11.6 |
The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health.
| score on a scale | Zanubrutinib |
|---|---|
| Baseline | 85.6 ± 15.5 |
| Week 12 | 78.8 ± 30.3 |
| Change from Baseline at Week 12 | -6.88 ± 23.0 |
| Week 24 | 78.1 ± 29.1 |
| Change from Baseline at Week 24 | -7.50 ± 21.9 |
Complement component 3 (C3) level in blood
| mg/dL | Zanubrutinib |
|---|---|
| Baseline | 116 ± 29.0 |
| Week 12 | 114 ± 16.7 |
| Change from Baseline at Week 12 | 1.86 ± 22.3 |
| Week 24 | 121 ± 23.7 |
| Change from Baseline at Week 24 | 6.43 ± 21.4 |
Complement component 4 (C4) level in blood
| mg/dL | Zanubrutinib |
|---|---|
| Baseline | 28.6 ± 14.1 |
| Week 12 | 31.5 ± 8.93 |
| Change from Baseline at Week 12 | 2.88 ± 9.51 |
| Week 24 | 31.0 ± 8.00 |
| Change from Baseline at Week 24 | 2.00 ± 11.6 |
| mg/dL | Zanubrutinib |
|---|---|
| Baseline | 1610 ± 578 |
| Week 12 | 1240 ± 286 |
| Change from Baseline at Week 12 | -368 ± 345 |
| Week 24 | 1200 ± 316 |
| Change from Baseline at Week 24 | -395 ± 570 |
| kU/L | Zanubrutinib |
|---|---|
| Baseline | 562 ± 396 |
| Week 12 | 1230 ± 1070 |
| Change from Baseline at Week 12 | 672 ± 965 |
| Week 24 | 1280 ± 1010 |
| Change from Baseline at Week 24 | 544 ± 817 |
| mg/dL | Zanubrutinib |
|---|---|
| Baseline | 572 ± 106 |
| Week 12 | 491 ± 67.0 |
| Change from Baseline at Week 12 | -80.8 ± 65.2 |
| Week 24 | 505 ± 125 |
| Change from Baseline at Week 24 | -71.2 ± 109 |
Change in erythrocyte sedimentation rate (ESR)
| mm/hr | Zanubrutinib |
|---|---|
| Baseline | 20.4 ± 19.7 |
| Week 12 | 9.00 ± 5.26 |
| Change from Baseline at Week 12 | -11.4 ± 15.9 |
| Week 24 | 8.75 ± 3.85 |
| Change from Baseline at Week 24 | -12.9 ± 18.6 |
Change in serum C-reactive protein (CRP) level
| mg/dL | Zanubrutinib |
|---|---|
| Baseline | 0.313 ± 0.0354 |
| Week 12 | 0.313 ± 0.0354 |
| Change from Baseline at Week 12 | 0 ± 0.0535 |
| Week 24 | 0.300 ± 0 |
| Change from Baseline at Week 24 | -0.0143 ± 0.0378 |
Number of participants with treatment-emergent adverse events (TEAEs).
| Participants | Zanubrutinib |
|---|---|
| TEAE | 10 |
| TEAE with Grade 3 or Higher | 2 |
| TEAE Related to Study Drug | 8 |
| TEAE Related to Study Drug with Grade 3 or Higher | 1 |
| TE Serious AE | 1 |
| TE Serious AE Related to Study Drug | 0 |
| TEAE Leading to Premature Discontinuation of Study Drug | 2 |
| TEAE Leading to Premature Discontinuation of Study | 2 |
Number of participants with any grade 3 or 4 treatment-emergent laboratory abnormality
| Participants | Zanubrutinib |
|---|---|
| Incidence of Safety Parameters Including Abnormal Laboratory Results | 2 |
Collected over Up to 32 weeks (24 weeks treatment plus 8 weeks follow-up). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zanubrutinib | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| Event | Zanubrutinib |
|---|---|
| COVID-19Infections and infestations | 1/10 |
| Event | Zanubrutinib |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/10 |
| Neutrophil count decreasedBlood and lymphatic system disorders | 2/10 |
| COVID-19Infections and infestations | 1/10 |
| LeukocytosisBlood and lymphatic system disorders | 1/10 |
| EosinophiliaBlood and lymphatic system disorders | 1/10 |
| AnemiaBlood and lymphatic system disorders | 1/10 |
| HematuriaRenal and urinary disorders | 1/10 |
| RashSkin and subcutaneous tissue disorders | 1/10 |
| UrticariaSkin and subcutaneous tissue disorders | 1/10 |
| Bullous pemphigoidSkin and subcutaneous tissue disorders | 1/10 |
| Age, Continuous(years) | Zanubrutinib |
|---|---|
| Mean | 58.2 ± 11.4 |
| Age, Customized(Participants) | Zanubrutinib |
|---|---|
| <50 years | 3 |
| >=50 years | 7 |
| Sex: Female, Male(Participants) | Zanubrutinib |
|---|---|
| Female | 3 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | Zanubrutinib |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Zanubrutinib |
|---|---|
| Asian | 6 |
| Black | 1 |
| White | 2 |
| Other | 1 |
| Region of Enrollment(Participants) | Zanubrutinib |
|---|---|
| United States | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Feb 2025, 30 months.
Results were first posted in Apr 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib
Immunoglobulin G4-Related Disease →
Matthew C. Baker